<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">porozendo</journal-id><journal-title-group><journal-title xml:lang="ru">Остеопороз и остеопатии</journal-title><trans-title-group xml:lang="en"><trans-title>Osteoporosis and Bone Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-2680</issn><issn pub-type="epub">2311-0716</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/osteo13183</article-id><article-id custom-type="elpub" pub-id-type="custom">porozendo-13183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>Новая гетерозиготная мутация в гене CDKN1B у пациентки с синдромом множественных эндокринных неоплазий 4 типа</article-title><trans-title-group xml:lang="en"><trans-title>A new heterozygous mutation in the CDKN1B gene in a patient affected by multiple endocrine neoplasia syndrome type 4</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9194-1302</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петросян</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrosyan</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петросян Альбина Сергеевна.</p><p>117036, Москва, ул. Дм. Ульянова, д.11</p><p>Researcher ID LKJ-8311-2024; Scopus Author ID 58492904500</p></bio><bio xml:lang="en"><p>Albina S. Petrosyan.</p><p>11 Dm. Ulyanova street, 117036 Moscow</p><p>Researcher ID LKJ-8311-2024; Scopus Author ID 58492904500</p></bio><email xlink:type="simple">Albinessa_p@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5952-5846</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бибик</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Bibik</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бибик Екатерина Евгеньевна - к.м.н.</p><p>Москва</p><p>Researcher ID AAY-3052-2020; Scopus Author ID 57195679482</p></bio><bio xml:lang="en"><p>Ekaterina E. Bibik - MD, PhD.</p><p>Moscow</p><p>Researcher ID AAY-3052-2020; Scopus Author ID 57195679482</p></bio><email xlink:type="simple">bibikaterina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8694-9679</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Салимханов</surname><given-names>Р. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Salimkhanov</surname><given-names>R. H.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Салимханов Рустам Халилович.</p><p>Москва</p><p>Scopus Author ID 57930716000</p></bio><bio xml:lang="en"><p>Rustam H. Salimkhanov.</p><p>Moscow</p><p>Scopus Author ID 57930716000</p></bio><email xlink:type="simple">rustam.salimkhanov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9258-2591</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovaleva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ковалева Елена Владимировна - к.м.н.</p><p>Москва</p><p>Researcher ID T-7397-2019; Scopus Author ID 928432</p></bio><bio xml:lang="en"><p>Elena V. Kovaleva - MD, PhD.</p><p>Moscow</p><p>Researcher ID T-7397-2019; Scopus Author ID 928432</p></bio><email xlink:type="simple">elen.v.kovaleva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6667-062X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Еремкина</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Eremkina</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Еремкина Анна Константиновна - к.м.н.</p><p>Москва</p><p>Researcher ID R-8848-2019</p></bio><bio xml:lang="en"><p>Anna K. Eremkina - MD, PhD.</p><p>Moscow</p><p>Researcher ID R-8848-2019</p></bio><email xlink:type="simple">eremkina.anna@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8144-4188</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уткина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Utkina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Уткина Марина Валерьевна - к.б.н.</p><p>Москва</p><p>Scopus Author ID 57191571945</p></bio><bio xml:lang="en"><p>Marina V. Utkina – PhD.</p><p>Moscow</p><p>Scopus Author ID 57191571945</p></bio><email xlink:type="simple">mv.utkina@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8520-8702</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трошина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Troshina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трошина Екатерина Анатольевна - д.м.н., профессор, член-корреспондент РАН.</p><p>Москва</p></bio><bio xml:lang="en"><p>Ekaterina A. Troshina - MD, PhD, Professor.</p><p>Moscow</p></bio><email xlink:type="simple">troshina@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-9742</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мокрышева</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Mokrysheva</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мокрышева Наталья Георгиевна - д.м.н., профессор, член-корреспондент РАН.</p><p>Москва</p></bio><bio xml:lang="en"><p>Natalya G. Mokrysheva - MD, PhD, Professor.</p><p>Moscow</p></bio><email xlink:type="simple">mokrisheva.natalia@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Национальный медицинский исследовательский центр эндокринологии<country>Россия</country></aff><aff xml:lang="en">Endocrinology Research Centre<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2024</year></pub-date><volume>27</volume><issue>4</issue><fpage>31</fpage><lpage>37</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Петросян А.С., Бибик Е.Е., Салимханов Р.Х., Ковалева Е.В., Еремкина А.К., Уткина М.В., Трошина Е.А., Мокрышева Н.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Петросян А.С., Бибик Е.Е., Салимханов Р.Х., Ковалева Е.В., Еремкина А.К., Уткина М.В., Трошина Е.А., Мокрышева Н.Г.</copyright-holder><copyright-holder xml:lang="en">Petrosyan A.S., Bibik E.E., Salimkhanov R.H., Kovaleva E.V., Eremkina A.K., Utkina M.V., Troshina E.A., Mokrysheva N.G.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.osteo-endojournals.ru/jour/article/view/13183">https://www.osteo-endojournals.ru/jour/article/view/13183</self-uri><abstract><p>Синдром множественных эндокринных неоплазий 4 типа (МЭН-4) — редкое аутосомно-доминантное заболевание, возникающее в результате мутации в гене CDKN1B, кодирующем регулятор клеточного цикла p27. В связи с редкостью патологии к настоящему времени собрано небольшое количество клинических наблюдений за пациентами с мутациями CDKN1B, при этом наличие генотип-фенотипических корреляций остается дискутабельным и требует дополнительного уточнения. При МЭН-4 в патологический процесс вовлекаются те же органы, что и при МЭН-1, однако возраст манифестации и течение заболевания могут отличаться. Мы представляем описание клинического случая пациентки с МЭН-4 с ранее не описанной в литературе мутацией в гене CDKN1B со сдвигом рамки считывания, которая привела к развитию первичного гиперпаратиреоза (ПГПТ) с множественным поражением околощитовидных желез (ОЩЖ) и пролактин-секретирующей микроаденомы гипофиза. Первым компонентом заболевания, диагностированным в возрасте 37 лет, была пролактинома. Позднее была выявлена висцеральная форма ПГПТ с изолированным поражением почек. Пациентке проводилось специфическое лечение указанных патологий с достижением удовлетворительных результатов. При комплексном обследовании значимого поражения других органов выявлено не было. Ограниченное число наблюдений за пациентами с мутациями в гене CDKN1B в настоящее время не позволяет определить закономерности течения этого заболевания, в связи с чем подробное описание клинической картины при новой выявленной мутации вносит значимый вклад в изучение данной патологии.</p></abstract><trans-abstract xml:lang="en"><p>Multiple endocrine neoplasia syndrome type 4 (MEN-4) is a rare autosomal dominant disease caused by mutation in the CDKN1B gene encoding the cell cycle regulator p27. Currently, a small number of clinical cases of patients with this pathology are known. Patterns of genotype-phenotype correlations in patients with CDKN1B mutations remains controversial and requires additional clarification. MEN-4 affects the same organs as MEN-1, however, the age of manifestation and the course of the disease may differ. We present the clinical case of a patient with MEN-4 with a new frame shift mutation in the CDKN1B gene caused PHPT with multiple parathyroid gland pathology and prolactin-secreting pituitary microadenoma. The first component of the disease diagnosed at the age of 37 was prolactinoma. Later, a visceral form of PHPT with isolated kidney complication was revealed. The patient has got the necessary treatment of the identified pathologies with satisfactory results. During a comprehensive examination, the involvement of other endocrine organs was not revealed. The limited number of case reports of patients with mutations in the CDKN1B gene currently does not allow us to determine the patterns of this syndrome’s course, and therefore a detailed description of the disease’s clinical presentation in a patient with a newly identified mutation makes a significant contribution to the study of this pathology.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>множественная эндокринная неоплазия</kwd><kwd>ингибитор циклин-зависимой киназы p27</kwd><kwd>гиперпаратиреоз</kwd><kwd>аденома гипофиза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multiple endocrine neoplasia</kwd><kwd>cyclin-dependent kinase inhibitor p27</kwd><kwd>hyperparathyroidism</kwd><kwd>pituitary adenoma</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Статья опубликована в рамках выполнения государственного задания НИР 123021300096-3 «Новые генетические предикторы (варианты) опухолевых и неопухолевых эндокринных заболеваний у взрослых, определяемые методом полноэкзомного секвенирования, в том числе в ядерных семьях» (2023-2025 гг.).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Singeisen H, Melanie Renzulli M, Pavlicek V, et al. Multiple endocrine neoplasia type 4: a new member of the MEN family. Endocr Connect. 2022;12(2). doi: https://doi.org/10.1530/ec-22-0411</mixed-citation><mixed-citation xml:lang="en">Singeisen H, Melanie Renzulli M, Pavlicek V, et al. Multiple endocrine neoplasia type 4: a new member of the MEN family. Endocr Connect. 2022;12(2). doi: https://doi.org/10.1530/ec-22-0411</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker R V, Frost M. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases. J Clin Endocrinol Metab. 2019;104(9). doi: https://doi.org/10.1210/jc.2019-00082</mixed-citation><mixed-citation xml:lang="en">Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker R V, Frost M. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases. J Clin Endocrinol Metab. 2019;104(9). doi: https://doi.org/10.1210/jc.2019-00082</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2). doi: https://doi.org/10.1016/j.mce.2013.08.002</mixed-citation><mixed-citation xml:lang="en">Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2). doi: https://doi.org/10.1016/j.mce.2013.08.002</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9). doi: https://doi.org/10.1210/jc.2012-1230</mixed-citation><mixed-citation xml:lang="en">Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9). doi: https://doi.org/10.1210/jc.2012-1230</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Мамедова Е.О., Мокрышева Н.Г., Пигарова Е.А., Пржиялковская Е.Г., Васильев Е.В., и др. Фенокопии синдрома множественных эндокринных неоплазий 1 типа: роль генов, ассоциированных с развитием аденом гипофиза // Проблемы Эндокринологии. — 2016. — Т. 62. — №4. — С. 4-10. doi: https://doi.org/10.14341/probl20166244-10</mixed-citation><mixed-citation xml:lang="en">Mamedova EO, Mokrysheva NG, Pigarova EA, et al. Phenocopies of multiple endocrine neoplasia type 1: Role of the genes, associated with the development of pituitary adenomas. Probl Endokrinol (Mosk). 2016;62(4). (In Russ.) doi: https://doi.org/10.14341/probl20166244-10</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kövesdi A, Tóth M, Butz H, et al. True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome. Endocrine. 2019;65(2). doi: https://doi.org/10.1007/s12020-019-01932-x</mixed-citation><mixed-citation xml:lang="en">Kövesdi A, Tóth M, Butz H, et al. True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome. Endocrine. 2019;65(2). doi: https://doi.org/10.1007/s12020-019-01932-x</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Мамедова Е.О., Димитрова Д.А., Белая Ж.E., Мельниченко Г.А. Роль некодирующих РНК в патогенезе синдрома множественных эндокринных неоплазий 1 типа // Проблемы Эндокринологии. — 2020. — Т. 66. — №2. — С. 4-12. doi: https://doi.org/10.14341/probl12413</mixed-citation><mixed-citation xml:lang="en">Mamedova EO, Dimitrova DA, Belaya ZE, Melnichenko GA. The role of non-coding RNAs in the pathogenesis of multiple endocrine neoplasia syndrome type 1. Probl Endokrinol (Mosk). 2020;66(2). (In Russ.) doi: https://doi.org/10.14341/probl12413</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fritz A, Walch A, Piotrowska K, et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002;62(11)</mixed-citation><mixed-citation xml:lang="en">Fritz A, Walch A, Piotrowska K, et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002;62(11)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(42). doi: https://doi.org/10.1073/pnas.0603877103</mixed-citation><mixed-citation xml:lang="en">Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(42). doi: https://doi.org/10.1073/pnas.0603877103</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Alevizaki M, Stratakis CA. Multiple endocrine neoplasias: advances and challenges for the future. J Intern Med. 2009;266(1):1-4. doi: https://doi.org/10.1111/j.1365-2796.2009.02108.x</mixed-citation><mixed-citation xml:lang="en">Alevizaki M, Stratakis CA. Multiple endocrine neoplasias: advances and challenges for the future. J Intern Med. 2009;266(1):1-4. doi: https://doi.org/10.1111/j.1365-2796.2009.02108.x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Seabrook A, Wijewardene A, De Sousa S, et al. MEN4, the MEN1 Mimicker: A Case Series of Three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. J Clin Endocrinol Metab. 2022;107(8). doi: https://doi.org/10.1210/clinem/dgac162</mixed-citation><mixed-citation xml:lang="en">Seabrook A, Wijewardene A, De Sousa S, et al. MEN4, the MEN1 Mimicker: A Case Series of Three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. J Clin Endocrinol Metab. 2022;107(8). doi: https://doi.org/10.1210/clinem/dgac162</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">D o i M, Hirayama J, Sassone-Corsi P. Circadian Regulator CLOCK Is a Histone Acetyltransferase. Cell. 2006;125(3). doi: https://doi.org/10.1016/j.cell.2006.03.033</mixed-citation><mixed-citation xml:lang="en">D o i M, Hirayama J, Sassone-Corsi P. Circadian Regulator CLOCK Is a Histone Acetyltransferase. Cell. 2006;125(3). doi: https://doi.org/10.1016/j.cell.2006.03.033</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12(18). doi: https://doi.org/10.1101/gad.12.18.2899</mixed-citation><mixed-citation xml:lang="en">Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12(18). doi: https://doi.org/10.1101/gad.12.18.2899</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Franklin DS, Godfrey VL, O’Brien DA, Deng C, Xiong Y. Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity. Mol Cell Biol. 2000;20(16). doi: https://doi.org/10.1128/mcb.20.16.6147-6158.2000</mixed-citation><mixed-citation xml:lang="en">Franklin DS, Godfrey VL, O’Brien DA, Deng C, Xiong Y. Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity. Mol Cell Biol. 2000;20(16). doi: https://doi.org/10.1128/mcb.20.16.6147-6158.2000</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005;102(41). doi: https://doi.org/10.1073/pnas.0503484102</mixed-citation><mixed-citation xml:lang="en">Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005;102(41). doi: https://doi.org/10.1073/pnas.0503484102</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">de Laat JM, van der Luijt RB, Pieterman CRC, et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 2016;14(1). doi: https://doi.org/10.1186/s12916-016-0708-1</mixed-citation><mixed-citation xml:lang="en">de Laat JM, van der Luijt RB, Pieterman CRC, et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 2016;14(1). doi: https://doi.org/10.1186/s12916-016-0708-1</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sambugaro S, Di Ruvo M, Ambrosio MR, et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region. Endocrine. 2015;49(1). doi: https://doi.org/10.1007/s12020-015-0540-y</mixed-citation><mixed-citation xml:lang="en">Sambugaro S, Di Ruvo M, Ambrosio MR, et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region. Endocrine. 2015;49(1). doi: https://doi.org/10.1007/s12020-015-0540-y</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Elston MS, Meyer-Rochow GY, Dray M, Swarbrick M, Conaglen JV. Early Onset Primary Hyperparathyroidism Associated with a Novel Germline Mutation in CDKN1B. Case Rep Endocrinol. 2015;2015. doi: https://doi.org/10.1155/2015/510985</mixed-citation><mixed-citation xml:lang="en">Elston MS, Meyer-Rochow GY, Dray M, Swarbrick M, Conaglen JV. Early Onset Primary Hyperparathyroidism Associated with a Novel Germline Mutation in CDKN1B. Case Rep Endocrinol. 2015;2015. doi: https://doi.org/10.1155/2015/510985</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Molatore S, Marinoni I, Lee M, et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: Clinical, genetic and functional characterization. Hum Mutat. 2010;31(11). doi: https://doi.org/10.1002/humu.21354</mixed-citation><mixed-citation xml:lang="en">Molatore S, Marinoni I, Lee M, et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: Clinical, genetic and functional characterization. Hum Mutat. 2010;31(11). doi: https://doi.org/10.1002/humu.21354</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Трухина Д.А., Мамедова Е.О., Лапшина А.М., Васильев Е.В., Тюльпаков А.Н., Белая Ж.Е. Морфологические характеристики аденом гипофиза в рамках фенокопий синдрома множественных эндокринных неоплазий 1 типа // Проблемы Эндокринологии. — 2021. — Т. 67. — №6. — С. 50-58. doi: https://doi.org/10.14341/probl12815</mixed-citation><mixed-citation xml:lang="en">Trukhina DA, Mamedova EO, Lapshina AM, Vasilyev E V., Tiulpakov AN, Belaya ZE. Morphological characteristics of pituitary adenomas in the phenocopy of multiple endocrine neoplasia type 1. Probl Endokrinol (Mosk). 2021;67(6). (In Russ. doi: https://doi.org/10.14341/probl12815</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Simonds WF. Expressions of Cushing’s syndrome in multiple endocrine neoplasia type 1. Front Endocrinol (Lausanne). 2023;14. doi: https://doi.org/10.3389/fendo.2023.1183297</mixed-citation><mixed-citation xml:lang="en">Simonds WF. Expressions of Cushing’s syndrome in multiple endocrine neoplasia type 1. Front Endocrinol (Lausanne). 2023;14. doi: https://doi.org/10.3389/fendo.2023.1183297</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
